What are monoclonal antibodies?
Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful antigens such as viruses. They are designed to block the virus’ attachment and entry into human cells.
This video, from Combat COVID, provides an excellent overview of monoclonal antibodies and how they can help high-risk patients.
What types of patients can benefit from treatment with monoclonal antibodies?
Your patient may be eligible for treatment with monoclonal antibodies if they have experienced the onset of mild to moderate symptoms of COVID-19 in the last 10 days, have tested positive for COVID-19, and have one or more of the following high-risk factors
- Are ≥65 years of age
- Body mass index (BMI) ≥35
- Chronic kidney disease
- Immunosuppressive disease
- Are currently receiving immunosuppressive treatment
- Are ≥55 years of age AND have
- cardiovascular disease, OR
- hypertension, OR
- chronic obstructive pulmonary disease/other chronic respiratory disease
- Are 12 to 17 years of age AND have
- BMI ≥85th percentile for their age and gender based on CDC growth charts, OR
- sickle cell disease, OR - congenital or acquired heart disease, OR
- neurodevelopmental disorders, for example, cerebral palsy, OR
- a medical-related technological dependence, for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19), OR
- asthma, reactive airway, or other chronic respiratory disease that requires daily medication for control.
Download the High-Risk-COVID-19-Patients guide from CombatCOVID.hhs.gov.
Where can a patient find monoclonal antibodies?
Once a high-risk individual is diagnosed, they need to know where they can go to get a monoclonal antibodies infusion. The two links below allow patients to search for infusion centers that are located closest to them in the state.
Fact sheets for healthcare providers
- Emergency Use Authorization (EUA) of Bamlanivimab and Etesevimab
- Emergency Use Authorization (EUA) of Casirivimab and Imdevimab